NEW YORK (GenomeWeb News) - ExonHit Therapeutics said today that it has amended its longstanding partnership with bioMerieux in order to gain commercial rights to cancer diagnostic kits developed through the agreement.
 
The amended agreement also gives bioMerieux “greater flexibility to initiate new research and development projects in that field,” ExonHit said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.